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OBJECTIVE—The angiopoietin-like protein 4 (Angptl4)/fasting-
induced adipose factor (Fiaf) is known as a regulator of periph-
eral lipid and glucose metabolism. In the present study, we
investigated the physiological role of Angptl4 in central regula-
tion of body weight homeostasis.
RESEARCH DESIGN AND METHODS—Hypothalamic An-
gptl4 expression levels were measured using immunoblot assay
during feeding manipulation or after administration of leptin,
insulin, and nutrients. The effects of Angptl4 on food intake, body
weight, and energy expenditure were determined following in-
tracerebroventricular (ICV) administration of Angptl4 in C57BL/6
mice. Food intake, energy metabolism, and feeding responses to
leptin, insulin, and nutrients were compared between Angptl4-
null mice and their wild littermates. Finally, the relationship of
hypothalamic AMP-activated protein kinase (AMPK) and Angptl4
was studied.
RESULTS—Hypothalamic Angptl4 expression levels were in-
creased upon food intake or administration of leptin, insulin, and
nutrients. Furthermore, central administration of Angptl4 sup-
pressed food intake and body weight gain but enhanced energy
expenditure. These effects were mediated via suppression of
hypothalamic AMPK activities. Consistently, Angptl4-null mice
displayed increased body weight and hypothalamic AMPK activ-
ity but reduced energy expenditure. Food intake following a fast
was signiﬁcantly greater in Angptl4-null mice, which was normal-
ized by centrally administered Angptl4. Moreover, anorectic
responses to leptin, insulin, and glucose were diminished in
Angptl4-null mice. In contrast, Angptl4-null mice were resistant
to diet-induced obesity, indicating obesity-promoting effects of
Angptl4 under the condition of fat-enriched diet.
CONCLUSIONS—We have demonstrated that hypothalamic
Angptl4 is regulated by physiological appetite regulators and
mediates their anorexigenic effects via inhibition of hypotha-
lamic AMPK activity. Therefore, Angptl4 appears to have an
important role in central regulation of energy metabolism.
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T
he past 20 years have witnessed a dramatic
increase in the obese population worldwide
(1). The hypothalamus is considered a key
player in the regulation of body weight (2),
although hypothalamic dysfunction may occur in
chronic energy excess state. Information on energy
intake and adiposity is relayed to hypothalamic neurons
and coordinated to eventually alter feeding behavior
and energy metabolism (3,4). In addition to the effectors
known to be implicated in this process (5), novel factors
may be involved.
Angiopoietin-like proteins (Angpts) are a family of pro-
teins with structures similar to those of angiopoietins,
NH2-terminal coiled coil domain (CCD), and COOH-termi-
nal ﬁbrinogen-like domain (FLD) (6,7). Angiopoietins con-
trol angiogenesis and vascular integrity via the Tie tyrosine
kinase receptors (8,9). Despite the structural similarities
between angiopoietins and Angptls, the latter do not bind
Tie receptors and have distinct biological functions
(6,10,11). Angptl3 is an important regulator of circulating
lipid concentrations (12), whereas Angptl6 is implicated in
body weight metabolism (10). A recent study has shown
that Angptl2 induces inﬂammation and insulin resistance
in adipose tissues from obese animals (13). These ﬁndings
collectively indicate that Angptls are active players in a
variety of metabolic processes.
Angptl4/fast-induced adipose factor (Fiaf) is a 50 kDa
glycoprotein originally identiﬁed as a target gene of the
nuclear receptors peroxisome proliferator–activated re-
ceptor (PPAR)- and PPAR- (7,11). Like Angptl3, Angptl4
is an important regulator of triglyceride metabolism (14).
Additionally, hepatic overexpression of Angptl4 improves
glucose tolerance despite promotion of hepatic fat accu-
mulation and hyperlipidemia (15). Fat-speciﬁc Angptl4
transgenic mice display a lean phenotype along with
enhanced fatty acid oxidation and lipolysis (16). Further-
more, intestinal Angptl4 mediates antiobesity effects in-
duced by germ-free conditions (17). These data suggest
that Angptl4 functions as an important regulator of periph-
eral energy metabolism. However, the potential role of
Angptl4 in central regulation of metabolism has yet to be
established.
In the present study, we describe critical evidence
showing that hypothalamic Angptl4 is an important
player in the regulation of body weight homeostasis.
RESEARCH DESIGN AND METHODS
Peptide synthesis. Mouse Angptl4 cDNA was ampliﬁed from the mouse liver
cDNA library by PCR using the following primer set: forward primer,
5-cctagctagccagaatcatgcgctgcgctc, and reverse primer, 5-gccgctcgagctaagag
gctgctgtagcct. Ampliﬁed DNA was cloned into the pAGCF vector (AdipoGen,
Incheon, Korea) and transfected into Cos7 cells using Hyperfect (AdipoGen).
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ampliﬁed, and cloned into expression vectors described as the above. For the
ampliﬁcation of CCD and FLD, the following primer sets were used: for CCD
ampliﬁcation, forward primer 5-cctagctagccagaatcatgcgctgcgctc and reverse
primer 5-cccgctcgagcttgtctactccattgtccag, and for FLD ampliﬁcation, forward
primer 5-ctagctagcaagaagctttccaagatgacc and reverse primer 5-cgcggatc
cctaagaggctgctgtagcct. Culture supernatant fractions were collected and
concentrated through ultraﬁltration. FLAG-tagged mouse Angptl4 was puriﬁed
using anti-FLAG afﬁnity column chromatography. Endotoxin was removed
with two consecutive column chromatography cycles using Detoxigel (Pierce,
Rockford, IL).
Animals. Adult male C57BL/6 and ob/ob mice were obtained from Japan SLC
(Hamamatsu, Japan). Angptl4
/ mice on a C57BL/6J genetic background
were generated as previously described (17) and kindly presented by Dr.
Andras Nagy. Mice were fed a standard chow diet (Samyang, Seoul, Korea) ad
libitum unless otherwise indicated. For feeding manipulation, mice were
starved overnight and refed for 4 h (fully fed state), followed by fasting and
refeeding for the indicated times. To generate diet-induced obesity (DIO),
mice were fed a high-fat diet (HFD) (60% fat, Research Diet) for 8 weeks. Lean
control mice were fed a low-fat diet (16% fat) over the same period. Animals
were housed under controlled temperature (23  1°C) conditions and
subjected to a 12-h light-dark cycle, with light from 0700 to 1900 h. All
procedures were approved by the Institutional Animal Care and Use Commit-
tee of the Asan Institute for Life Sciences.
Cell culture. Primary hypothalamic neuron cultures were prepared from
fetal rat brains obtained on embryonic day 18 as previously described (18).
Differentiation was induced by culturing cells in neurobasal medium (Invitro-
gen) supplemented with 5 g/ml insulin, 100 /ml iron-free human transferrin,
100 mol/l putrescin, 30 nmol/l sodium selenite, and 20 nmol/l progesterone
for 7–8 days.
Cannulation and injection. Stainless steel cannulae (26 gauge; Plastics One)
were implanted into the third cerebral ventricle (ICV) of mice as previously
described (19). Following a 7-day recovery period, the correct positioning of
each cannula was conﬁrmed by a positive dipsogenic response to angioten-
sin-2 (50 ng/mouse). Angptl4, insulin, glucose, leptin, and 5-aminoimidazole-
4-carboxyamide ribonucleoside (AICAR) were dissolved in 0.9% saline, as well
as 5-tetradecyloxy-2-furoic acid (TOFA) (Yuhan Research Institute, Seoul,
Korea) dissolved in 100% DMSO, and administered via ICV injection in a total
volume of 2.5 l, respectively. The majority of feeding studies were performed
in the early light phase in animals subjected to overnight fasting. Food intake
and body weight were monitored for 24 h postinjection.
Energy expenditure and locomotor activity. Energy expenditure was
measured using an Oxymax apparatus (Columbus Instruments) over 24 h after
a 3-day acclimatization period. The behavioral test was performed between
1400 and 1800 h. Mice were individually housed and allowed to acclimatize for
1 h in individual transfer cages to the behavioral testing room. Locomotor
activity was evaluated using an Activity Monitor (MED Associates), compris-
ing an open-ﬁeld chamber (43.2  43.2  30.5 cm) containing 16  16
photocells for measuring horizontal movements. Locomotor activity was
measured as the total distance traveled for 60 min.
Immunoblotting. Animals were killed by decapitation 2 h following the
administration of Angptl4, leptin, insulin, and nutrients. After injection, mice
were fasted until they were killed. The medial part of the hypothalamus was
dissected in the anterior border of optic chiasm, posterior border of the
mammillary body, upper border of anterior commissure, and lateral border
halfway from the lateral sulcus in the ventral side of brain. Immunoblot
analysis was conducted as described earlier (20). Tissue lysates (30- to 50-g
samples) were separated by 8% SDS-PAGE and transferred to a polyvinylidine
ﬂuoride membrane. For immunoblot assay of plasma Angptl4, plasma was
diluted with lysate buffer (1:500) and 5 ul of diluted plasma was loaded.
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FIG. 1. Expression and regulation of hypothalamic Angptl4. A: Double immunoﬂuorescence staining of Angptl4 and neuron marker MAP2 in the
hypothalamic arcuate nucleus from normal mice. B: Changes in protein expression levels of full-length Angptl4 in the hypothalamus (Hypo), liver,
white adipose tissue (WAT), and plasma during the fasting (F) and refeeding (RF) periods (n  5–6). *P < 0.05 and **P < 0.005 vs. the full-fed
(FF) group. †P < 0.05 and ‡P < 0.005 vs. the 24-h fasted group. C: Hypothalamic Angptl4 expression in leptin-deﬁcient ob/ob mice with or without
leptin treatment (n  5–6). *P < 0.01 vs. C57BL/6 mice. †P < 0.05 vs. ob/ob mice with no leptin treatment. D: Effect of intracerebroventricular
administration of insulin on hypothalamic Angptl4 expression (n  4). *P < 0.01 vs. saline-injected control. E and F: Changes in hypothalamic
Angptl4 expression following food intake or ICV administration of 3 g leptin and 3 mU insulin in HFD-fed obese mice. *P < 0.01 between
indicated groups. Data are presented as means  SEM. NS, not signiﬁcant. (A high-quality digital representation of this ﬁgure is available in the
online issue.)
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night at 4°C with antibodies against Angptl4 (1:1,500, rabbit; AdipoGen),
phosphorylated (Thr 172), and total forms of AMP-activated protein kinase
(AMPK) or phosphorylated (Ser 79) and total acetyl CoA carboxylase (ACC)
(Cell Signaling). Blots were developed using horseradish peroxidase–linked
anti-rabbit secondary antibody and the chemiluminescent detection system
(Perkin Elmer). Band density was measured with a densitometer (VersaDoc
Multi Imaging Analyzer System; BIO-RAD) and corrected based on the density
of 	-actin or total forms of AMPK and ACC.
Immunoﬂuorescence. C57BL/6 mice were perfused with 4% paraformalde-
hyde through the heart under anesthesia for 15 min following a 5-h fast.
Following postﬁxation and the dehydration process, coronal brain sections
(15 m thick) were obtained using cryostat (Leica,Wetzlar, Germany) and
incubated with primary antibodies against Angptl4 (1:200, goat; Santa Cruz)
and microtubule-associated protein 2 (MAP2) (1:800, mouse; Sigma) or glial
ﬁbrillary acid protein (GFAP) (1:300, mouse; Sigma) at 4°C for 48 h. After
washing, slides were incubated with Alexa-Fluor 546–conjugated donkey
anti-goat antibody and Alexa-Fluor 488–conjugated donkey anti-mouse anti-
bodies (Invitrogen) at room temperature for 1 h. For nuclear staining, slides
were treated with DAPI (1:20,000; Invitrogen) for 10 min before mounting.
Triple immunoﬂuorescence was examined using confocal microscopy (Leica).
The speciﬁcity of Angptl4 antibody was tested in Angptl4
/ mice (data not
shown).
Measurement of AMPK activity. Medial hypothalamus and soleus muscle
was lysed with digitonin buffer. Tissue lysate (40 g) was immunoprecipitated
by incubation with speciﬁc antibodies against the 1- and 2-AMPK catalytic
subunits (Cell signaling) and 20 l of 25% (wt/vol) protein G-sepharose beads
(Santa Cruz Biotechnology) overnight at 4°C. AMPK activity was measured
using a modiﬁed method of Davies et al. (21).
Statistical analysis. Data are presented as means  SEM. Statistical analysis
was performed using SPSS-PC14. The statistical signiﬁcance among the
groups was tested using one-way ANOVA followed by a post hoc LSD test or
an unpaired Student’s t test where appropriate. Repeated ANOVA was
employed for analysis of body weight data from Angptl4
/ mice experiments.
Two-way ANOVA was used to analyze the effects of leptin, insulin, and glucose
in Angpt4l
/ mice and ICV Angptl4 in DIO mice. Signiﬁcance was deﬁned as
P 
 0.05.
RESULTS
Hypothalamic Angptl4 expression is regulated by
hormones and nutrients. We ﬁrstly investigated Angptl4
expression in the brain from C57BL/6 normal mice. An-
gptl4 was ubiquitously expressed in hypothalamus, cere-
brum, and cerebellum (supplementary Fig. 1, available in
the online appendix [http://diabetes.diabetesjournals.org/
cgi/content/full/db10-0145/DC1]). Double immunoﬂuores-
cence staining revealed that Angptl4 was coexpressed
with neuronal marker MAP2 but not with glial marker glial
ﬁbrillary acid protein in the hypothalamic arcuate nucleus
(Fig. 1A and supplementary Fig. 2). Moreover, Angptl4 was
secreted by primary cultured hypothalamic neurons and
SH-SY5Y neuron cells (supplementary Fig. 3). Taken to-
gether, Angptl4 secreted from the hypothalamic neurons
may function in an autocrine and paracrine manner,
although Angptl4 receptors remained yet to be cloned.
We next investigated whether Angptl4 expression levels
in the medial hypothalamus were affected by nutritional
status. Several studies have shown that fasting and food
restriction lead to elevated Angptl4 expression levels in
the plasma, adipose tissue, and liver (7,11,22). Consis-
tently, full-length Angptl4 protein levels in the liver, white
adipose tissue, and plasma were increased upon starvation
of normal mice and decreased following food intake (Fig.
1B). In contrast, hypothalamic Angptl4 expression was
decreased during a fast and increased following food
intake and oral ingestion of glucose, protein, and lipid
(Fig. 1B and supplementary Fig. 4). Thus, Angptl4 expres-
sion in central and peripheral tissues was differentially
regulated by fuel supply. On the other hand, we observed
no remarkable differences in truncated Angptl4 expression
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FIG. 2. Effects of Angptl4 on food intake, body weight, and energy expenditure. A and B: ICV injection of full-length mouse Angptl4 led to
decreased food intake and body weight for 24 h postinjection (n  6–7). *P < 0.005 vs. saline-injected controls. C and D: Comparison of the effects
of Angptl4 full-length, FLD, and CCD fragments on food intake and body weight (n  5–6). *P < 0.05 and **P < 0.01 vs. saline-injected controls.
E: Energy expenditure over a 24-h period following ICV injection of saline or 0.1 nmol Angptl4. *P < 0.05 vs. saline-injected controls. F: ICV
injection of 0.1 nmol Angptl4 caused a greater weight loss even in the fasted condition (n  8–9). *P < 0.05 vs. saline-injected controls. G and
H: The inhibitory effects of leptin and Angptl4 on food intake and body weight were blunted in obese mice (n  5–6). *P < 0.05 vs. saline-injected
controls. Data are presented as means  SEM.
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amus (data not shown).
Leptin, a potent anorexigenic hormone, suppressed An-
gptl4 expression in the adipose tissue (7). By contrast,
hypothalamic Angptl4 expression was reduced in leptin-
deﬁcient (ob/ob) mice and was increased by leptin treat-
ment (1 mg  kg
1  day
1 for 3 days via intraperitoneal
injection) (Fig. 1C). In normal mice, insulin (3 mU) and
leptin (3 g) elevated hypothalamic Angptl4 expression
levels when administered intracerebroventricularly fol-
lowing an overnight fast (Fig. 1D and supplementary Fig.
5). Thus, it appeared that hypothalamic Angptl4 expres-
sion was upregulated by the appetite suppressing-hor-
mones leptin and insulin. Feeding-, leptin-, and insulin-
induced increases in hypothalamic Angptl4 levels were
signiﬁcantly blunted in HFD-fed obese mice (Fig. 1E and
F), suggesting that the normal regulatory processes affect-
ing hypothalamic Angptl4 levels were disrupted in obese
animals.
Central administration of Angptl4 causes anorexia
and weight loss. To gather insight into the role for
hypothalamic Angptl4 in body energy homeostasis, we
administered full-length mouse Angptl4 (0.03–1 nmol) via
ICV cannulae to overnight-fasted mice. A single ICV ad-
ministration of Angptl4 led to potent suppression of food
intake and body weight gain during the 24-h postinjection
period (Fig. 2A and B). Intraperitoneal administration of
large amounts of Angptl4 (1 and 3 mg/kg) caused a modest
and short-lasting reduction in food intake and body weight
(supplementary Fig. 6). Thus, Angptl4 seems to regulate
body weight metabolism mainly through central
mechanisms.
To identify the domain of Angptl4 responsible for the
central metabolic actions, we generated the NH2-terminal
CCD and COOH-terminal FLD fragments of mouse An-
gptl4. Angptl4 full length, CCD, and FLD (0.1 nmol each)
were administered in fasted mice to compare their effects
on food intake and body weight. ICV administration of
FLD, but not CCD, caused a signiﬁcant reduction in food
intake and body weight (Fig. 2C and D), indicating that
Angprl4-induced anorexia and weight loss may be medi-
ated via FLD.
We additionally tested whether hypothalamic Angptl4
was involved in central regulation of energy metabolism.
For this, we monitored energy expenditure for a 24-h
period following ICV injection of Angptl4 (0.1 nmol).
Notably, energy expenditure was increased by ICV injec-
tion of Angptl4; the effect lasted over 24 h postinjection
(Fig. 2E). In addition, ICV Angptl4 caused a greater weight
loss compared with ICV saline even in the fasted condition
(Fig. 2F), suggesting that enhanced energy expenditure
may contribute to Angptl4-induced reduction in body
weight. These ﬁndings collectively imply that central ad-
ministration of Angptl4 triggers a negative energy balance
by suppressing energy intake and also by stimulating
energy expenditure.
Obese animals have defects in production of satiety
signals in the hypothalamus. To test whether abnormal
response to Angptl4 may be associated with this defect,
we compared the feeding responses to Angptl4 and leptin
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FIG. 3. Metabolic phenotypes of Angptl4-deﬁcient mice. A and B: Increased body weight and fat mass in Angptl4
/ male mice (n  56). A: left
panel, males; right panel, females. *P < 0.05 vs. wild-type littermates. C and D: Reduced energy expenditure and locomotor activity in Angptl4
/
male mice aged 20 weeks (n  4). *P < 0.05 vs. Angptl4
/ mice. E: Food intakes in the freely fed state in Angptl4
/ mice.
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g ICV) induced anorexia and weight loss in lean mice,
which was signiﬁcantly attenuated in DIO mice (Fig. 2G
and H). Based on these ﬁndings, we propose that impaired
hypothalamic Angptl4 activity may contribute to the
pathogenesis of obesity. We additionally tested the rela-
tionship between leptin and Angptl4 in feeding regulation.
The anorexigenic effects of Angptl4 (0.l nmol) were well
preserved in leptin-deﬁcient (ob/ob) and leptin receptor–
deﬁcient (db/db) mice (supplementary Fig. 7). These ﬁnd-
ings suggest that leptin and leptin receptors are not critical
for Angptl4-caused anorexia.
Angptl4-null mice develop obese phenotypes. To fur-
ther explore the function of Angptl4 in body weight
homeostasis, we determined body weight changes in
Angptl4
/ mice. In general, Angptl4
/ male mice were
modestly heavier than their wild (Angptl4
/) littermates
(Fig. 3A). Increased body weight was not due to acceler-
ated growth because body lengths did not differ between
wild and knockout mice (supplementary Fig. 8). Consis-
tently, epidydimal fat pad weight was greater in
Angptl4
/ male mice at 20 weeks of age (Fig. 3B).
However, limited differences in body weight were ob-
served between female Angptl4
/ and Angptl4
/ mice
(Fig. 3A), suggesting that Angptl4-null phenotypes were
affected by sex.
To establish the mechanisms underlying increased body
weight of Angptl4
/ mice, we assessed energy metabo-
lism, locomotor activity, and food intake. Angptl4
/ male
mice displayed lower energy expenditure, especially dur-
ing the light-on period, and a tendency toward decreased
locomotor activities (Fig. 3C and D). Food consumption
when food was freely available was not signiﬁcantly
altered in Angptl4
/ mice (Fig. 3E). However, marked
hyperphagia and greater weight gain were observed when
Angptl4
/ mice resumed food intake following an over-
night fast (Fig. 4A and B). These ﬁndings raise the possi-
bility that lack of hypothalamic Angptl4 causes aberrant
hypothalamic signaling of satiety. This hypothesis is sup-
ported by the ﬁnding that central administration of An-
gptl4 (0.1 nmol) completely reversed fast-induced
hyperphagia in Angptl4
/ mice (Fig. 4C).
We further determined whether feeding responses to
leptin, insulin, or glucose were impaired in Angptl4
/
mice. The early anorexigenic effects of leptin (3 g),
insulin (three mU), and glucose (0.75 mg) were attenuated
in Angptl4
/ mice (Fig. 4D). The late anorexigenic and
weight-reducing effects of insulin and glucose were also
diminished in Angptl4
/ mice, whereas leptin-induced
delayed anorexia and weight loss were preserved (Fig. 4E
and F). These results, in conjunction with hypothalamic
Angptl4 expression data, indicate that hypothalamic
Angptl4 mediates the effects of insulin, leptin, and glucose
on food intake and body weight. However, the delayed
effects of leptin occur via an Angptl4-independent
mechanism.
Angptl4 inhibits hypothalamic AMPK activity. AMPK
is a serine-threonine kinase that plays a key role in the
recovery from energy-depleted conditions (23). AMPK is
expressed in hypothalamic neurons and functions as an
important signaling molecule mediating the feeding effects
of leptin, insulin, glucose, melanocortins, and -lipoic acid
(24–26). Accordingly, we examined whether hypothalamic
AMPK may serve as a downstream signaling pathway of
Angptl4.
ICV injection of 0.1 nmol Angptl4 decreased hypotha-
FIG. 4. Decreased satiety signals in Angptl4-deﬁcient mice. A and B: Food intake and body weight gain were greater in Angptl4
/ mice over a 24-h
refeeding period. *P < 0.05 and **P < 0.005 vs. Angptl4
/ littermates. C: ICV injection of Angptl4 before reestablishment of food intake suppressed
fast-induced hyperphagia in Angptl4
/ mice. *P < 0.05 vs. saline-injected Angptl4
/ mice. †P < 0.05 vs. saline-injected Angptl
/mice. D-F: Effects of
ICV administration of leptin, insulin, and glucose on food intake and body weight in Angptl4
/ mice aged 8–12 weeks (n  5–6). *P < 0.05 vs.
saline-injected groups. †P < 0.05 vs. Angptl4
/ mice injected with the same agents. Data are presented as means  SEM.
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tion, in overnight-fasted mice (Fig. 5A). Hypothalamic
1 and 2 isoform-speciﬁc AMPK activities were also
reduced by 74 and 55%, respectively, following Angptl4
administration (Fig. 5B). In parallel, ICV Angptl4 sup-
pressed hypothalamic levels of phosphorylated ACC, a
well-known downstream target of AMPK (Fig. 5C),
which would result in increased ACC activity. In cul-
tured hypothalamic neurons, treatment with Angptl4
also suppressed AMPK phosphorylation (Fig. 5D). Con-
sistently, Angptl4
/ mice had higher hypothalamic
AMPK activity compared with their wild littermates
(Fig. 5E), conﬁrming the inhibitory actions of Angptl4
on hypothalamic AMPK.
Similarly to feeding effects, FLD fragment had a
suppressive effect on hypothalamic AMPK activity,
while CCD had no effect (Fig. 5F). Moreover, Angptl4-
induced reduction in hypothalamic AMPK activity was
attenuated in DIO mice (Fig. 5G). This may provide a
molecular mechanism via which DIO mice were resis-
tant to exogenous Angptl4 (Fig. 2H). Interestingly, cen-
tral administration of Angptl4 (0.1 nmol) tended to
increase 2-AMPK activity in skeletal muscle at 2 h and
6 h postinjection (Fig. 5H). Thus, central administration
of Angptl4 appears to have an opposing effect on
hypothalamic and muscle AMPK. Angptl4-derived in-
crease in skeletal muscle AMPK activity may stimulate
fatty acid oxidation (27), leading to increased energy
expenditure as seen in Fig. 2E.
Hypothalamic AMPK mediates the anorexigenic ef-
fect of Angptl4. Finally, we investigated whether An-
gptl4-induced AMPK inhibition is essential for the
anorexigenic effects of Angptl4. For this, we injected the
AMPK activator AICAR (30 pmol) 1 h prior to 0.1 nmol
Angptl4 injection via ICV cannulae in overnight-fasted
mice. The AICAR dose was selected based on our prelim-
inary study showing no signiﬁcant increase in food intake
or body weight at this concentration. As expected, ICV
AICAR alone did not alter food intake or body weight.
However, coadministration of AICAR prevented Angptl4-
induced anorexia and weight loss, conﬁrming an impor-
tant role for hypothalamic AMPK as a downstream
signaling molecule for Angptl4 (Fig. 6A and B).
In hypothalamic neurons, decreased AMPK activity
leads to elevated malonyl CoA levels through ACC
activation (28). Accumulating evidence has shown that
increased hypothalamic malonyl CoA levels are associ-
ated with anorexia (29,30). In our study, the ICV admin-
istration of ACC inhibitor TOFA (2 g), which would
reduce malonyl CoA levels, blocked the anorexigenic
and weight-reducing effects of Angptl4 (Fig. 4C and D).
These data conﬁrm the hypothesis that elevation in
hypothalamic malonyl CoA levels is important for the
anorexigenic actions of many appetite regulators includ-
ing Angptl4 (Fig. 4E).
DISCUSSION
Our ﬁndings ﬁrstly demonstrate that hypothalamic Angptl4
is engaged in the regulation of feeding behavior and body
weight metabolism. The role for hypothalamic Angptl4 in
feeding regulation is further supported by the ﬁnding that
ICV administration of Angptl4 corrects the impaired sati-
ety generation in Angptl4-deﬁcient mice. Previous studies
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FIG. 5. Suppressive effects of Angptl4 on hypothalamic AMPK activity. A–C: ICV administration of 0.1 nmol Angptl4 decreased AMPK, ACC
phosphorylation, and 1- and 2-speciﬁc AMPK activities in the medial hypothalamus at 2 h postinjection (n  5). *P < 0.05 and **P < 0.005 vs.
saline-injected controls. D: Effect of Angptl4 on AMPK phosphorylation in primary cultured hypothalamic neurons. P < 0.05 vs. untreated
controls. E: Hypothalamic 2-AMPK activities in 24-week-old Angptl4
/ mice (n  4). *P < 0.05 vs. Angptl4
/ littermates. F: Effects of
full-length, CCD, and FLD fragments of Angptl4 on hypothalamic AMPK activities. Hypothalamus was collected at 2 h postinjection (n  5–6).
*P < 0.05 and **P < 0.01 vs. saline. G: ICV injection of 0.1 nmol Angptl4 did not alter hypothalamic AMPK activity in DIO mice (n  4–5). (H)
Effect of ICV injection of 0.1 nmol Angptl4 on 2-AMPK activities in soleus muscle. Muscle was collected 2 h and 6 h post–ICV injection (n  4–5).
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eral lipid metabolism– and gut microbiota–associated
mechanisms (16,17). Thus, we propose that Angptl4 gov-
erns adiposity through both central and peripheral
mechanisms.
In the hypothalamus, Angptl4 appears to act as a
common downstream mediator of physiological anorex-
igenic factors such as insulin, leptin, and glucose. This
notion is evidenced by the fact that administration of
insulin, leptin, or glucose increased hypothalamic
Angptl4 expression levels. Furthermore, anorectic re-
sponses to insulin, leptin, and glucose were reduced in
Angptl4-deﬁcient mice. However, the delayed effects of
leptin on food intake and body weight were well pre-
served in Angptl4-null mice, suggesting that Angptl4 is
not involved in the late actions of leptin.
Notably, hypothalamic Angptl4 expression patterns
regulated to food availability were reciprocal to those in
peripheral tissues. Similarly, Angptl4 expression levels
in hypothalamic and adipose tissues were differentially
regulated by leptin (7). Nutrient-dependent alterations
in hypothalamic Angptl4 protein content were not in
line with changes in Angptl4 mRNA levels (supplemen-
tary Fig. 9). On the other hand, leptin and insulin
administration signiﬁcantly increased the relative
amounts of full-length versus truncated Angptl4 (sup-
plementary Fig. 5). Therefore, metabolism-related regu-
lation of hypothalamic Angptl4 activity may occur in the
process of degradation to less effective truncated
Angptl4.
The appetite regulators such as leptin, insulin, and
ghrelin exert their actions through regulation of hypotha-
lamic AMPK activity (25,31). In the present study, hypo-
thalamic AMPK activity was suppressed upon Angptl4
administration but enhanced in Angptl4-null mice. More-
over, forced activation of hypothalamic AMPK prevented
Angptl4-induced anorexia and weight loss. Thus, central
metabolic effects of Angptl4 occur, at least in part, through
suppression of hypothalamic AMPK activity. As depicted
in Fig. 6E, an Angptl4-induced decrease in AMPK activity
promotes a de novo fatty acid synthesis pathway in the
hypothalamus by increasing hypothalamic ACC activities.
Indeed, administration of ACC inhibitors blocked the
effects of Angptl4 on food intake and body weight. These
ﬁndings further support the important role of hypotha-
lamic fatty acid metabolism pathway in appetite
regulation.
Given that hypothalamic Angptl4 is an important regu-
lator of feeding behavior, obesity may be associated with
abnormalities in hypothalamic Angptl4. In our study, DIO
mice were unable to elevate anorexigenic Angptl4 in the
hypothalamus in response to food intake, leptin, and
insulin. Furthermore, the effects of exogenous Angptl4 on
food intake and hypothalamic AMPK activity were signif-
icantly reduced in obese mice. Thus, dysregulation of
hypothalamic Angptl4 may contribute to the pathogenesis
FIG. 6. Hypothalamic AMPK mediates the central actions of Angptl4. A-D: Prior ICV administration of the AMPK activator, AICAR, and ACC
inhibitor TOFA blocked the effects of Angptl4 on food intake and body weight (n  6). *P < 0.05 vs. saline-injected controls. †P < 0.05 vs. Angptl4
alone–treated group. Data are presented as means  SEM. E: Diagram summarizing the ﬁndings of the study. Hypothalamus Angptl4 is
upregulated by leptin, insulin, and nutrients, which is impaired in obese mice. Increased hypothalamic Angptl4 causes anorexia and weight loss
through regulation of hypothalamic AMPK and ACC activities. (A high-quality color representation of this ﬁgure is available in the online issue.)
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Angptl4 regulation and actions may have a therapeutic
potential for obesity.
Because Angptl4 inhibits the lipoprotein lipase activity
(32), overexpression of Angptl4 was expected to suppress
fat storage in the adipose tissues. Consistently, Angptl4
transgenic mice generated using AP2 promoter had re-
duced body fat mass coupled with elevated plasma lipid
levels (16). The effects of Angptl4 overexpression were
ampliﬁed by an HFD, resulting in markedly elevated
plasma lipid levels and impaired glucose tolerance in
Angptl4 transgenic mice fed a HFD. However, there was
not a report on whether Angptl4-transgenic mice were
susceptible or resistant to DIO. We unexpectedly found
that Angptl4-null mice were resistant to DIO, whereas on
chow they displayed increased body weight (supplemen-
tary Fig. 10). The anti-obesity phenotype of Angptl4-null
mice upon a fat-rich meal is hardly understandable at
present and needs further investigations to unveil the
metabolic action of Angptl4 in fat-abundant nutritional
environment.
In summary, we identiﬁed hypothalamic Angptl4 as a
new physiological regulator of body weight metabolism.
However, to gain more insight into the central role of
Angptl4, it would be of interest to examine the pheno-
type of neuronal Angptl4-deﬁcient mice in the future.
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